Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study).
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2012
At a glance
- Drugs Atomoxetine; Methylphenidate
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms EMD
- Sponsors Eli Lilly
- 01 Jun 2012 Actual patient number is 23 according to ClinicalTrials.gov.
- 06 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2010 Actual initiation date added to 1 Jun 2010 as reported by ClinicalTrials.gov.